MX2022007521A - Anticuerpos contra la integrina alfa 11 beta 1. - Google Patents

Anticuerpos contra la integrina alfa 11 beta 1.

Info

Publication number
MX2022007521A
MX2022007521A MX2022007521A MX2022007521A MX2022007521A MX 2022007521 A MX2022007521 A MX 2022007521A MX 2022007521 A MX2022007521 A MX 2022007521A MX 2022007521 A MX2022007521 A MX 2022007521A MX 2022007521 A MX2022007521 A MX 2022007521A
Authority
MX
Mexico
Prior art keywords
beta
integrin alpha
antibodies against
antibodies
against integrin
Prior art date
Application number
MX2022007521A
Other languages
English (en)
Inventor
Elma Kurtagic
Iii James W Meador
Jr Christopher Beneduce
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2022007521A publication Critical patent/MX2022007521A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción incluye anticuerpos que se unen específicamente a la integrina alfa 11 beta 1 (a11ß1), así como métodos para elaborar y utilizar tales anticuerpos.
MX2022007521A 2019-12-20 2020-12-18 Anticuerpos contra la integrina alfa 11 beta 1. MX2022007521A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962951723P 2019-12-20 2019-12-20
US202062983155P 2020-02-28 2020-02-28
US202063054717P 2020-07-21 2020-07-21
PCT/US2020/066107 WO2021127500A1 (en) 2019-12-20 2020-12-18 Antibodies against integrin alpha 11 beta 1

Publications (1)

Publication Number Publication Date
MX2022007521A true MX2022007521A (es) 2022-07-19

Family

ID=76478574

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007521A MX2022007521A (es) 2019-12-20 2020-12-18 Anticuerpos contra la integrina alfa 11 beta 1.

Country Status (17)

Country Link
US (1) US20230050972A1 (es)
EP (1) EP4076525A4 (es)
JP (1) JP2023508286A (es)
KR (1) KR20220123013A (es)
CN (1) CN115135342A (es)
AU (1) AU2020407124A1 (es)
BR (1) BR112022012093A2 (es)
CA (1) CA3165386A1 (es)
CL (1) CL2022001673A1 (es)
CO (1) CO2022010204A2 (es)
CR (1) CR20220288A (es)
DO (1) DOP2022000129A (es)
EC (1) ECSP22056627A (es)
IL (1) IL294047A (es)
MX (1) MX2022007521A (es)
PE (1) PE20221723A1 (es)
WO (1) WO2021127500A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4263605A2 (en) * 2020-12-18 2023-10-25 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1
WO2023238845A1 (ja) * 2022-06-07 2023-12-14 アステラス製薬株式会社 加齢疾患の治療又は予防のための抗インテグリンα１１抗体を含む医薬組成物
WO2023250415A2 (en) * 2022-06-22 2023-12-28 Momenta Pharmaceuticals, Inc. Antibodies against integrin alpha 11 beta 1 and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
WO2008075045A1 (en) * 2006-12-18 2008-06-26 Cartela R & D Ab Binding agents to the integrin alpha-11 subunit, and uses thereof
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
EP3517549A1 (en) * 2018-01-24 2019-07-31 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
EP3524625A1 (en) * 2018-02-08 2019-08-14 Bergen Teknologioverforing AS Antibody against alpha-11 integrin and its use
JP7440718B2 (ja) * 2018-03-01 2024-02-29 恭之 横崎 抗インテグリンα１１モノクローナル抗体、およびその利用

Also Published As

Publication number Publication date
CA3165386A1 (en) 2021-06-24
KR20220123013A (ko) 2022-09-05
WO2021127500A9 (en) 2021-07-29
JP2023508286A (ja) 2023-03-02
CL2022001673A1 (es) 2023-02-03
US20230050972A1 (en) 2023-02-16
AU2020407124A1 (en) 2022-07-21
ECSP22056627A (es) 2022-11-30
CO2022010204A2 (es) 2022-10-21
DOP2022000129A (es) 2022-10-31
PE20221723A1 (es) 2022-11-04
EP4076525A4 (en) 2024-05-01
CR20220288A (es) 2022-10-07
EP4076525A1 (en) 2022-10-26
WO2021127500A1 (en) 2021-06-24
BR112022012093A2 (pt) 2022-08-30
CN115135342A (zh) 2022-09-30
IL294047A (en) 2022-08-01

Similar Documents

Publication Publication Date Title
MX2022007521A (es) Anticuerpos contra la integrina alfa 11 beta 1.
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
MY201526A (en) Anti-trem2 antibodies and methods of use thereof
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
CR20210057A (es) Anticuerpos anti-sortilina y métodos para su uso
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
CR20220078A (es) Anticuerpos anti-ms4a4a y métodos de uso de los mismos
ZA202008095B (en) Humanized antibodies against psma
MX2021012692A (es) Anticuerpos anti-mertk y sus metodos de uso.
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
SA521420953B1 (ar) بروتين ربط مولد ضد مضاد لـمولد ضد ظهاري ذو 6 أغشية انتقالية من البروستاتا 1
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
MX2022016300A (es) Anticuerpo anti-trop2.
MX2020013172A (es) Anticuerpos anti-siglec-7 y sus metodos de uso.
MX2023006777A (es) Composiciones y métodos que comprenden antagonistas de proteína 2 relacionada con frizzled secretada (sfrp2).
MX2022003159A (es) Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos.
MX2022007156A (es) Metodos de uso de anticuerpos anti-cd33.